BCR-ABL tyrosine kinase inhibitor (TKI)-induced nephropathy: An under-recognized phenomenon

Leuk Res Rep. 2020 Jun 8:14:100211. doi: 10.1016/j.lrr.2020.100211. eCollection 2020.

Authors

Michele Stanchina¹, Zoe McKinnell¹, Jae H Park², Eytan M Stein², Sheng F Cai^{1

2}, Justin Taylor^{1

2

3}

Affiliations

¹ Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
² Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
³ University of Miami Sylvester Comprehensive Cancer Center, Miami, FL, USA.

No abstract available

Keywords: Bcr-abl; Chronic myeloid leukemia; Dasatinib; Imatinib; Nilotinib; Ponatinib.

Grants and funding

P30 CA008748/CA/NCI NIH HHS/United States